# Complexities in the Diagnosis and Management of Anti-Hu Antibody-Associated Paraneoplastic Syndrome

## TL;DR

This paper presents a complex case of a patient with anti-Hu antibody-associated paraneoplastic syndrome, highlighting the challenges in diagnosis and treatment.

## Contribution

The paper contributes a detailed case study emphasizing the diagnostic and management difficulties of anti-Hu antibody-associated paraneoplastic syndrome.

## Key findings

- The patient exhibited neurological symptoms and was found to have anti-Hu antibodies and a pre-sacral mass.
- Despite immunoglobulin treatment, the patient showed no significant clinical improvement.
- The case underscores the need for early diagnosis and a multidisciplinary approach in managing paraneoplastic syndromes.

## Abstract

Anti-Hu is the most commonly associated antibody in paraneoplastic syndromes (PNS) - mainly secondary to small cell lung cancer (SCLC), breast cancer, thymoma, and lymphoma. This case is about a 65-year-old female patient presenting with slurred speech, headache, and loss of balance for one day. On examination, she was found to have downbeat and bilateral gaze-evoked nystagmus, dysarthria, and bilateral intention tremors. The rest of the neurological examination was unremarkable. Upon investigation, a CT scan showed a pre-sacral mass and a PET scan showed a lobulated soft tissue mesenteric mass at L5/S1, thought to possibly be a gastrointestinal stromal tumour, and mediastinal lymph nodes including right lower pre-tracheal, subcarinal and right hilar lymph nodes. Additionally, paraneoplastic antibody testing was positive for anti-Hu antibodies. She was given a five-day course of intravenous immunoglobulin without significant clinical improvement. The patient was discharged on a fast-track pathway and did not undergo chemotherapy, radiotherapy or surgical resection as the primary tumour could not be diagnosed.

Paraneoplastic antibodies are a family of autoantibodies occurring as a result of malignancy that act to recognize antigens in the brain, resulting in a variety of neurological manifestations. Despite well-known literature on this entity, PNS is notoriously difficult to diagnose and manage. The first step in the management of PNS is to treat the underlying malignancy. Beyond this, the other key component of PNS treatment is immune modulation which may involve immunosuppression with high-dose corticosteroids, IV immunoglobulins, plasma exchange or plasmapheresis. It is therefore important for PNS to be diagnosed early and to adopt a comprehensive multidisciplinary approach to improve the outcomes of those presenting with PNS.